Senti Bio Strengthens Leadership Team with Strategic Hires

Core Viewpoint - Senti Biosciences, Inc. has expanded its senior leadership team by appointing Jay Cross as CFO and Faraz Siddiqui as SVP of Technical Operations to drive strategic growth and enhance clinical development efforts [1][2]. Leadership Appointments - Jay Cross will oversee financial strategy, operations, and investor relations starting March 3, 2025, bringing a wealth of experience from previous roles, including a successful capital markets campaign that raised over $100 million [1][2]. - Faraz Siddiqui, who joined in January 2025, will manage process development, manufacturing, and supply chain, leveraging over 27 years of biopharmaceutical experience [1][3]. Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, which aims to enhance precision and control in therapies [4]. - The company's lead program, SENTI-202, has shown promising early clinical data, achieving MRD-negative complete remissions in 2 of 3 patients, with durability of 4+ and 3+ months as of December 2024 [4]. Strategic Goals - The appointments of Cross and Siddiqui are expected to support the advancement of Senti Bio's clinical pipeline and optimize manufacturing strategies as the company prepares for further clinical development beyond Phase 1 trials [2][3].